Johnson & Johnson's Rybrevant Faspro Just Left the Infusion Chair. Halozyme Fell 15.7%. The Subcutaneous Wave Is Now a Courtroom Story

On Nov. 5, 2026, the FDA granted accelerated approval to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic head-and-neck squamous cell carcinoma whose disease progressed after platinum chemotherapy and an anti-PD-(L)1 antibody. The label excludes HPV-associated oropharyngeal cancers, which is where the immunotherapy salvage setting performs best. It is the first approval of a dual-targeted therapy in this setting, hitting EGFR and MET with one molecule, and the first dual-targeted agent available subcutaneously. In the phase 1b/2 OrigAMI-4 trial, 102 previously treated patients posted a 42% response rate confirmed by blinded independent central review (95% CI 32%–52%), with 15% complete responses, and 56% of responders stayed in response beyond six months.

The molecule did not change. Amivantamab still binds EGFR and MET, still carries a rash profile that stopped treatment in 1.5% of patients, and still arrives every three weeks in the monotherapy setting. What changed is the cost of delivering it. The approval is the third step in a fast sequence: subcutaneous amivantamab was first approved in EGFR-mutated lung cancer on Dec. 17, 2025, then won once-a-month dosing in February 2026, and now moves into a tumor type where the standard of care is another antibody. Continued approval of the head-and-neck indication depends on the phase 3 OrigAMI-5 study, which puts subcutaneous amivantamab with carboplatin and pembrolizumab in first-line recurrent or metastatic disease, sothe confirmatory trial must convert a 42% response rate into a survival argument before the indication becomes permanent.

Every infusion generates two revenue streams: the drug's sales, and the delivery margin on the chair, the nurse and the hours around it. Converting a therapy to subcutaneous splits the second stream away from the hospital and hands it to whoever can absorb the volume fastest, while the first stream stays with the manufacturer. That is why the shiftmoves the delivery margin off the hospital infusion chair and onto home infusion providers, specialty pharmacy and physician offices. The price of a chair hour is set by what fills it, and a five-minute injection frees capacity that a multi-hour infusion had occupied.

The pricing of that trade showed up in October 2026, when CD&R and McKesson agreed to take Option Care Health private at $32.05 a share, a roughly $5.8 billion enterprise value and about 37% above the Oct. 5 close, with closing expected in the first half of 2027. Option Care withdrew guidance and stopped hosting earnings calls because of the transaction, and still grew net revenue 4.1%. Its shares closed Nov. 6 at $31.65, a spread of about 1% to the cash offer. The acquirers are not paying for the chair. They are paying for the ability to reach a patient wherever the drug goes, which is exactly where subcutaneous oncology is heading.

Halozyme owns the enzyme, not the drug. Its ENHANZE platform is recombinant human hyaluronidase, and the 2025 Form 10-K describes the royalties partners pay on ENHANZE collaborations as averaging in the mid-single digits of their sales. That single line of chemistry is the whole point: every conversion to a five-minute injection adds a royalty-bearing version of a drug that previously carried no enzyme license for Halozyme. Nine-month 2026 royalties reached $889.4 million, up 46% year over year, and management raised full-year royalty guidance to $1.235 billion–$1.255 billion.

Which is why the durability of that annuity stopped being an abstract patent question in 2026 and became a live fight with the largest player in oncology, one that refuses to pay the toll at all. Halozyme sued Merck in April 2025 over the subcutaneous Keytruda formulation, won a preliminary injunction in Germany on Dec. 4, 2025, and on Oct. 7, 2026 won a Dutch court order barring manufacture, offering, import and stocking of Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. Investors who bought Halozyme as a royalty annuity are really buying an outcome in that docket.

Halozyme reported third-quarter results on Nov. 5, 2026: revenue of $493.0 million, up 39%; record royalties of $341.0 million, up 44%; GAAP net income of $247.0 million and non-GAAP diluted earnings of $2.39 a share. Management raised full-year guidance to $1.860 billion–$1.925 billion of revenue, $1.235 billion–$1.255 billion of royalties and $8.75–$9.05 of non-GAAP earnings. The next session the shares fell 15.7% to $103.63. The approval changed nothing measurable in the royalty line, and the market noticed.

Merck's answer to the subcutaneous wave was to build its own version. Keytruda Qlex contains berahyaluronidase alfa rather than Halozyme's enzyme, so Merckpaid Halozyme no enzyme royalties and kept the subcutaneous margin itself. It is working at speed, and it is working because of logistics rather than science: sales went from $128 million in the first quarter of 2026 to $463 million in the second and $830 million in the third, roughly 10% of an $8.6 billion Keytruda franchise in a single quarter. The slope of that curve changed when a permanent J-code took effect on April 1, 2026, and Merck won approval in Japan under the KEYJECT brand in the third quarter.

Enforcement is jurisdiction-specific, and 2026 proved it. The same family of patents that a Dutch court enforced in October was held unpatentable by an American tribunal three months earlier. For a business whose asset is a mid-single-digit percentage of someone else's sales, that is not a footnote. It is the difference between a compounding royalty annuity and a litigation bill.

Read down that table and the arrangement is clear. The manufacturer sells the drug, the licensee owns the enzyme and collects the toll, the independent operator moves the drug to the patient, and the distributor owns the channel that reaches them. The November approval adds a line to the manufacturer's revenue and a few million dollars at most to the licensor, while the logistics chain sees nothing new unless the site of care actually moves. That is the test to watch: not how many subcutaneous approvals arrive, but how many of them are administered somewhere other than an infusion suite.

Nov. 5, 2026 produced a genuine first-in-class approval, a five-minute injection that removes hours of chair time, and a franchise that now reaches beyond lung cancer into a tumor type where every other option is another antibody. It also produced a stock that fell 15.7% the next session, because the approval changes almost nothing in the royalty line while one court's patent ruling changes everything about whether that line is defensible. For Johnson & Johnson, the approval widens a franchise that grew 62.3% in the quarter and gives amivantamab a credible shot at first-line head and neck. For Halozyme, the approval is a rounding error next to the Merck litigation. For Merck, the conversion curve is the strategy and the injunction is the threat to it. For argenx and Bristol Myers Squibb, the subcutaneous format keeps paying a toll they can afford because their own products are the ones being converted.

The trade is between companies that own the delivery technology and companies that pay for it, and the next twelve months will show which side of the patent line each one sits on. At the Nov. 6 close of $103.63, Halozyme was trading at roughly 11.6 times the midpoint of its own raised earnings guidance, which is a fair price for a business whose royalties grew 46% over nine months and whose durability is being litigated.The market now prices the litigation rather than the approval, and that is the correct order of priorities for anyone underwriting the subcutaneous wave. Facts here: the approval, the trial data, the guidance and the rulings. Inference: how much of the toll survives them. Speculation: whether the first-line head-and-neck data eventually makes amivantamab the most valuable member of its own family.